Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Tucatinib
Related studies linked through entity extraction aliases.
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
- Status
- SUSPENDED
- Phase
- PHASE2
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Tucatinib Together With Pembrolizumab and Trastuzumab
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response
- Status
- COMPLETED
- Phase
- PHASE2
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A